February 22, 2022
Professor Barry Halliwell is Senior Advisor, Academic Appointments and Research Excellence, Office of the Senior Deputy President and Provost.
Professor Halliwell graduated from the University of Oxford with BA (1st class) and D.Phil degrees. He holds a D.Sc degree from the University of London. He was a faculty member with the University of London, King’s College from 1974 to 2000 and held a prestigious Lister Institute Research fellowship. From 1995 to 1999, he was a Visiting Research Professor of Internal Medicine and Biochemistry with the University of California Davis, School of Medicine, Divisions of Cardiology and Pulmonary/Critical Care Medicine. Professor Halliwell was a Visiting Professor of Biochemistry to NUS from 1998 to 2000. He was Head of the University’s Department of Biochemistry from 2000 to 2007 and was Deputy Director, Office of Life Sciences from 2001 to 2003. From 2003 to September 2008, he was the founding Executive Director of the newly-formed NUS Graduate School of Integrative Sciences and Engineering. From Mar 2006 to May 2015, he was the Deputy President (Research and Technology) at NUS. From Jun 2015 to May 2018, he was the Senior Advisor to the President at the National University of Singapore.
An internationally-acclaimed biochemist, Professor Halliwell is known especially for his seminal work on the role of free radicals and antioxidants in biological systems. The Thomson Reuters lists Professor Halliwell as one of the world’s most highly-cited researchers in Biology and Biochemistry and his Hirsch Index is 164. (Based on Scopus, Jun 2021).
His book Free Radicals in Biology and Medicine published by Oxford University Press, and now in its fifth edition, is regarded worldwide as an authoritative text in the field. He has received numerous research awards, including Singapore President’s Science and Technology Medal (2013), the “Lifetime Achievement Award” by the Society for Free Radical Biology and Medicine in the USA for overall sustained excellence in the field and the Ken Bowman Research Award for outstanding achievements in the field of cardiovascular research from the Institute of Cardiovascular Sciences (Canada).
His research focuses on the role of free radicals and antioxidants in human disease, particularly Alzheimer’s disease and other brain disorders. His interest in identifying the most important antioxidants in the human diet and in developing novel antioxidants has critical bearing on treating human diseases and understanding how diet might cause or prevent them.
Professor Halliwell is a member of several editorial boards including FEBS Letters, Biochemical and Biophysical Research Communications and Antioxidants and Redox Signaling. He has been a lead speaker at Gordon Conferences and other prestigious events worldwide and is a member of several expert advisory panels to leading universities, companies and government agencies.
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system